BIND Therapeutics
0 followers
BIND
Performance
About BIND Therapeutics
BIND Therapeutics was a biotechnology company specializing in the development of targeted polymeric nanoparticle therapeutics, known as ACCURINS®, designed to deliver treatment directly to specific cells and tissues. Incorporated in 2006, the company's innovative approach aimed to improve therapeutic outcomes beyond traditional methods. In 2016, Pfizer acquired most of BIND Therapeutics' assets and continues to develop the ACCURINS® technology.
Recent News
No recent news for this company.
Recent Deals
No recent deals for this company.